{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-118839","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.243260+00:00","generated_at":"2026-05-21T16:20:25.347290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Verrica Q1 2025: YCANTH revenue $3.4M; dispensed 10,102 units (+16.7% QoQ)","bullets":["Net loss $9.7M ($0.10/share) vs. $20.3M ($0.44) in Q1 2024; non-GAAP net loss $7.8M.","YCANTH revenue $3.4M from >10K applicator units dispensed, a company record and 16.7% sequential growth.","Cash and equivalents $29.6M as of March 31, 2025.","Appointed Noah Rosenberg as CMO (March) and Gavin Corcoran to Board (April).","Completed end-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); global Phase 3 for common warts advancing with Torii."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-118839","json":"https://secwatch.observer/filing/0001193125-25-118839.json","markdown":"https://secwatch.observer/filing/0001193125-25-118839.md","text":"https://secwatch.observer/filing/0001193125-25-118839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525118839/0001193125-25-118839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525118839/d88474d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:20:25.347290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}